780 BRANNAN STREET, SAN FRANCISCO, CA
Annual Meeting Results; Election of Directors at Olema Pharmaceuticals
Announces Clinical Trial Collaboration and Supply Agreement to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Reports First Quarter 2026 Financial and Operating Results
Material disclosure
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CFO Departure - Shane Kovacs Leaves Olema Pharmaceuticals
Q1
FY 2025
Q3
Q2
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence